Palmitoylation-related Gene Expression and Its Prognostic Value in Ovarian Cancer: Insights into Immune Infiltration and Therapeutic Potential

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 18

PMID 39692826

Authors

Shaoying Zeng

Lijian Zeng

Xiaoying Xie

Liang Peng

Affiliations

Soon will be listed here.

Abstract

Background: Palmitoylation, a key post-translational modification, plays a significant role in ovarian cancer (OV) progression. However, the impact of palmitoylation-related genes on genomic instability, immune infiltration, and therapeutic response in OV remains poorly understood. This study aimed to investigate these factors to facilitate risk stratification and therapeutic intervention, providing insights into personalized treatment strategies.

Methods: Data from TCGA and GEO were utilized to develop a prognostic model based on palmitoylation-related genes. Differential expression, functional enrichment, and immune infiltration analyses were performed. Immune cell composition and pathway activities in different risk groups were assessed using CIBERSORT and ssGSEA algorithms. Immunotherapy response was predicted using TIDE and SubMap, while drug sensitivity differences were evaluated using the GDSC database.

Results: Univariate, LASSO, and multivariate Cox regression analyses identified palmitoylation-related genes with significant prognostic value. The prognostic model effectively stratified patients into high- and low-risk groups, demonstrating significant survival differences. Immune infiltration analysis revealed distinct immune cell compositions and functions between risk groups. Low-risk patients exhibited higher immune scores and increased expression of immune checkpoints (PD-1, CD274, CTLA4), suggesting greater response to immunotherapy. Drug sensitivity analysis identified compounds with differential efficacy between risk groups, highlighting potential targeted treatment options.

Conclusion: Palmitoylation-related genomic features significantly influence OV progression and the immune landscape, offering potential for improved risk stratification and informing immunotherapy strategies to enhance patient outcomes.

References

Li H, Zimmerman S, Weyemi U . Genomic instability and metabolism in cancer. Int Rev Cell Mol Biol. 2021; 364:241-265. DOI: 10.1016/bs.ircmb.2021.05.004. View

Konstantinopoulos P, Matulonis U . Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023; 4(9):1239-1257. DOI: 10.1038/s43018-023-00617-9. View

Yuan Y, Li P, Li J, Zhao Q, Chang Y, He X . Protein lipidation in health and disease: molecular basis, physiological function and pathological implication. Signal Transduct Target Ther. 2024; 9(1):60. PMC: 10940682. DOI: 10.1038/s41392-024-01759-7. View

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

Zhao S, Ye Z, Stanton R . Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols. RNA. 2020; 26(8):903-909. PMC: 7373998. DOI: 10.1261/rna.074922.120. View

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

Hoshida Y, Brunet J, Tamayo P, Golub T, Mesirov J . Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One. 2007; 2(11):e1195. PMC: 2065909. DOI: 10.1371/journal.pone.0001195. View

Wang Y, Lu H, Fang C, Xu J . Palmitoylation as a Signal for Delivery. Adv Exp Med Biol. 2020; 1248:399-424. DOI: 10.1007/978-981-15-3266-5_16. View

Yuan X, Li Z, Zhao H, Bai J, Zhang J . Accurate Inference of Tumor Purity and Absolute Copy Numbers From High-Throughput Sequencing Data. Front Genet. 2020; 11:458. PMC: 7205152. DOI: 10.3389/fgene.2020.00458. View

10.

Boegel S, Castle J, Kodysh J, ODonnell T, Rubinsteyn A . Bioinformatic methods for cancer neoantigen prediction. Prog Mol Biol Transl Sci. 2019; 164:25-60. DOI: 10.1016/bs.pmbts.2019.06.016. View

11.

Li M, Zhang L, Chen C . Diverse Roles of Protein Palmitoylation in Cancer Progression, Immunity, Stemness, and Beyond. Cells. 2023; 12(18). PMC: 10526800. DOI: 10.3390/cells12182209. View

12.

Zhu H, Hu H, Hao B, Zhan W, Yan T, Zhang J . Insights into a Machine Learning-Based Palmitoylation-Related Gene Model for Predicting the Prognosis and Treatment Response of Breast Cancer Patients. Technol Cancer Res Treat. 2024; 23:15330338241263434. PMC: 11363247. DOI: 10.1177/15330338241263434. View

13.

Liu J, Kong X, Huang T, Wang R, Li W, Chen Q . Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study. Front Immunol. 2020; 11:2048. PMC: 7539667. DOI: 10.3389/fimmu.2020.02048. View

14.

Ko P, Dixon S . Protein palmitoylation and cancer. EMBO Rep. 2018; 19(10). PMC: 6172454. DOI: 10.15252/embr.201846666. View

15.

Xiang K, Zhang M, Yang B, Liu X, Wang Y, Liu H . TM-Score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer. Int Immunopharmacol. 2024; 134:112224. DOI: 10.1016/j.intimp.2024.112224. View

16.

Stewart C, Ralyea C, Lockwood S . Ovarian Cancer: An Integrated Review. Semin Oncol Nurs. 2019; 35(2):151-156. DOI: 10.1016/j.soncn.2019.02.001. View

17.

Lin A, Zhang J, Luo P . Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Front Immunol. 2020; 11:2039. PMC: 7435056. DOI: 10.3389/fimmu.2020.02039. View

18.

Chen D, Shao M, Meng P, Wang C, Li Q, Cai Y . GSA: an independent development algorithm for calling copy number and detecting homologous recombination deficiency (HRD) from target capture sequencing. BMC Bioinformatics. 2021; 22(1):562. PMC: 8609767. DOI: 10.1186/s12859-021-04487-9. View

19.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

20.

Zhang D, Zhang X, Liu Z, Han T, Zhao K, Xu X . An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma. Front Oncol. 2023; 13:1207068. PMC: 10327293. DOI: 10.3389/fonc.2023.1207068. View